For example, EMT-TFs (ZEB1, SNIAL, SLUG) have been demonstrated to confer resistance to oxaliplatin and cisplatin in breast, ovarian, colon, and pancreatic cancers (Guo et al., 2012; Lim et al., 2013). Here, SNAI2 is linked to pancreatic neoplasm.